Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSAH9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,269
Award facts
- Contract value 100% obligated
- $10,269.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $10,269.28 by the Defense Logistics Agency on January 9, 2026, for EXPAREL 266 mg/20 mL vials. This firm fixed-price delivery order, with an ultimate completion date of February 2, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to provide comprehensive pharmaceutical supply to Department of Defense healthcare facilities worldwide.
EXPAREL is a specialty surgical product used for local anesthetic infiltration during surgical procedures. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with its product portfolio encompassing branded and generic pharmaceuticals, biologics, vaccines, and specialty surgical products. The company's underlying IDC with DLA was awarded on November 13, 2025, with a ceiling value of approximately $500 billion and an ultimate completion date of December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting recurring medical supply needs of the military healthcare system globally.
Quick answers
Who was awarded contract SPE2DR26FSAH9?
SPE2DR26FSAH9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FSAH9 worth?
The government has obligated $10,269 on SPE2DR26FSAH9.
Is contract SPE2DR26FSAH9 an order under another contract?
Yes. SPE2DR26FSAH9 is a delivery order under SPE2DR25D9332, an indefinite delivery contract.
Was contract SPE2DR26FSAH9 competed?
The extent of competition for SPE2DR26FSAH9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award